ABSTRACT-Ebelactone B (EB) (10-'-10-' M) inhibited dose-dependently carboxypeptidase (CP) Y-like exopeptidase, one of the major kininases separated from rat urine, whereas it inhibited neither CPA, CPB or neutral endopeptidase (NEP). Degradation of bradykinin (BK) to BK-(1-8) in rat urine was completely inhibited by EB (10-5 M) with the increased generation of BK-(1-7). Intraduodenal administration of EB (3 mg/kg) to anesthetized rats caused marked diuresis (by 110%) and natriuresis (130%), in parallel with the increase in urinary kinin levels (110%). Intravenous infusion of a BK antagonist, Hoe140 (3 mg/kg/hr), strongly blocked both EB-induced diuresis and natriuresis. EB may be a novel type of diuretic and natriuretic agent that acts by increasing urinary kinin levels. Bradykinin (BK) is very active in renal function because it participates in increasing the renal blood flow and in di uresis and natriuresis (1). We have reported that the degra dation pathway of BK in rat urine is quite different from that in plasma because of the difference in kininases present (2). The major kininases in rat urine were neutral endopeptidase (NEP) and carboxypeptidase (CP) Y-like exopeptidase (3), whereas angiotensin converting enzyme (ACE) and CPN mainly degrade BK in rat plasma (2).
Bradykinin (BK) is very active in renal function because it participates in increasing the renal blood flow and in di uresis and natriuresis (1) . We have reported that the degra dation pathway of BK in rat urine is quite different from that in plasma because of the difference in kininases present (2) . The major kininases in rat urine were neutral endopeptidase (NEP) and carboxypeptidase (CP) Y-like exopeptidase (3), whereas angiotensin converting enzyme (ACE) and CPN mainly degrade BK in rat plasma (2) .
Ebelactones, isolated from actinomycetes, were report ed to inhibit some enzymes such as esterase, lipase and N formylmethionine aminopeptidase (4) . In the present paper, we report that Ebelactone B (EB) selectively in hibited not only CPY from yeast but also CPY-like exopep tidase in rat urine without inhibition of other kininases in plasma and urine. Furthermore, administration of EB to anesthetized rats caused diuresis and natriuresis via in creased urinary kinin excretion. This suggests that EB is a candidate for a new type of diuretic and natriuretic agent. NEP and CPY-like exopeptidase in rat urine were sepa rated by using a Superdex 200 column as described in the previous paper (3) . Plasma samples were prepared from blood collected from the carotid artery under ether anesthesia (2) . Enzyme activities of isolated CPA, CPB and CPY were determined with peptide substrates: Z-Gly Phe for CPA (5), Bz-Gly-Arg for CPB (6) and Z-Phe-Leu for CPY (7) . Assays of kininase activity and detection of BK fragments were carried out by HPLC (2, 3) . The in vivo effects of EB were studied in male Sprague-Dawley strain rats (SPF, 280-350g, 8 to 10-week-old, anesthetized with sodium pentobarbital, 40 mg/kg, i.p.). Urine was collected through a polyethylene cannula inserted into the bladder to estimate the volume of urine and urinary so dium and potassium levels. Physiological saline was in fused (6 ml/kg/hr) via the jugular vein throughout the experimental period. Urine volume was estimated by its weight, and urinary sodium and potassium levels were as sayed by flame photometry (8) . For the assay of kinin in the urine, urine was collected directly into plastic tubes containing absolute ethanol through a polyethylene can nula inserted into both ureters under pentobarbital anesthesia, since kinin is rapidly degraded during its stay in the bladder. The amounts of kinin in the extracts were determined by enzyme immunoassay kits (Markit M bradykinin; Dainippon Pharmaceutical Corp., Osaka) (9) . EB, supplied by Institute of Microbial Chemistry (Tokyo) was administered (1 or 3 mg/kg, dissolved in DMSO at 3.3 or 10 mg/ml) intraduodenally. Control rats were given DMSO (0.3 ml/kg) alone. Urine was collected for 15 min before and 1 hr after the drug treatment.
The following enzymes and inhibitors were used: CPA from bovine pancreas and CPB from porcine pancreas (Sigma Chemical Co., St. Louis, MO, USA), CPY from yeast (Oriental Yeast Co., Ltd., Tokyo), MGTA (D,L-2 mercaptomethyl-3-guanidinoethyl-thiopropanoic acid), an inhibitor of CPN (Carbiochem Corp, La Jolla, CA, USA), Z-Phe-Leu (Bachem Corp., Rubendorf, Switzer land), phosphoramidon, an inhibitor of NEP, Z-Gly-Phe and Bz-Gly-Arg (Peptide Institute, Osaka). Table 1 .
Effect of ebelactone B on CPA, B, Y and kininases from rat urine Table 2 . Effect of ebelactone B on the degradation of bradykinin in rat urine or plasma
The paired t-test was used to evaluate the significance of difference, and a P value less than 0.05 was considered to be significant. As shown in Table 1 , EB completely inhibited the activ ity of CPY at 10-5 M, whereas it had no effect on those of CPA and CPB at the same dose. EB also inhibited the activity of CPY-like exopeptidase (IC50: 3.3 x 10-7 M), separated from rat urine, in a concentration-dependent manner (10-7-10-5 M) without affecting the activity of NEP. Rat urine degraded BK at the first step into BK (1 8) (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe) through the action of a CPY-like exopeptidase and into BK-(1-7) (Arg-Pro-Pro-Gly-Phe-Ser-Pro) by NEP (3). As shown in Table 2a , the generation of BK-(1 8) from BK in rat urine was inhibited by EB (10-'M) with an increased amount of BK- (1-7) . This increase in BK-(l-7) genera tion may be attributable to the slow degradation of the substrate BK by CPY inhibition. The generation of BK (1 7) was inhibited by phosphoramidon (10-4 M). The combination of both inhibitors completely inhibited the generation of both BK fragments. Although we previous ly reported that BK-(1 -6) was a stable metabolite of BK in rat urine (2), the amount of BK-(1-6) generated in the present experiment was scanty, suggesting less total kininase activity in the present urine samples. Captopril (Sankyo Pharmaceutical Co., Ltd., Tokyo) had no effect on the generation of both degradation products of BK, in dicating that the kininase activity in rat urine was attribut Fig. 1 . Effects of Ebelactone B (EB) on urinary kinin levels (A), urine volume (B), urinary sodium levels (C) and urinary potassium levels (D) in anesthetized rats. EB (3 mg/kg) was administered intraduodenally. Urine samples for 15 min were col lected 15 min before EB (Pre) and 1 hr after EB (Post). Hoel40, a bradykinin antagonist, was infused (3 mg/kg/hr) intravenous ly from 15 min before EB for 75 min. Each value represents the mean ±S.E.M. from four animals. The post-value was com pared with the pre-value in each group of animals (paired t-test, *P < 0.05, ***P <0.001). -• Ebelactone B, J Ebelactone B + Hoe 140, / Vehicle.
able to both NEP and the CPY-like exopeptidase, but not ACE. In rat plasma (Table 2b) , BK was degraded to BK (1 8) by CPN and to BK- (1 7) by ACE, and both frag ments were further degraded to BK-(1-5) (Arg-Pro-Pro Gly-Phe) by ACE (2). EB had no effect on the generation of these BK fragments. Captopril inhibited the generation of BK-(1 7) and BK-(1 5), whereas MGTA inhibited the generation of BK-(1 8) alone. Treatment of anesthetized rats with EB (3 mg/kg, in traduodenally) markedly increased the kinin levels in urine, collected from ureters 1 hr after the administration of EB, from 3.6± 1.6 to 7.5 ± 1.4 pg/!i1 (by 110%, P < 0.05), whereas the control rats receiving only the vehi cle did not show any changes in urinary kinin excretion (Fig. IA) . This increase in kinin excretion was accompa nied with the marked increase in urine volume from 78.0±7.9 to 166.4± 18.0 1.1/15 min (by 110%, P <0.001) (Fig. IB) . When a low dose of EB (1 mg/kg) was ad ministered, the increase in the urine volume was from 84.0±11. 5 to 124.6± 14.61&15 min (by 48%, n=3, P<0.05). The urine volume of the vehicle control rats was not changed, and the values were 85.2-L5.8 and 87.2 ± 10.8 fill 15 min before and 1 hr after the treatment, respectively (Fig. I B) . Urinary sodium levels were marked ly increased by EB (3 mg/kg) treatment by 110% (Fig.  1 C) (P<0.05) , whereas urinary potassium levels were kept fairly constant (Fig. 1D) . Even a low dose of EB (1 mg/kg) caused a significant (P<0.05) increase (by 56%) in urinary sodium levels. The intraduodenal administra tion of EB (3 mg/kg) treatment reduced the total kininase activity by 25%. EB administration (3 mg/kg) did not change the systemic blood pressure, and the mean blood pressure before and 1 hr after the EB-treatment were 112 ± 15 mmHg and 109 ± 12 mmHg (n = 3), respectively.
Intravenous infusion of a sufficient amount (8) of the bradykinin antagonist Hoel40 (3 mg/kg/hr, Hoechest, Frankfult, Germany) from 15 min before EB administra tion (3 mg/kg) for 75 min cancelled the EB-induced in crease in urine volume and urinary sodium levels (Fig. 1 , B and C). Urinary potassium levels were not affected by an antagonist treatment (Fig. 1D) .
We reported in a previous paper (3) the presence of a CPY-like exopeptidase in rat urine, although members of the CPY family were also reported to act as a protective protein in association with lysosomal beta galactosidase and neuraminidase in mouse kidney (10) and a deaminase from human platelets (11) . However, the physiological roles of urinary CPY-like exopeptidase were not clear. In the present paper, we found that EB, which was originally reported to inhibit a methylesterase (12) and an acylpep tide hydrolase (13) by modification of an active site ser ine, inhibited urinary CPY-like exopeptidase in rats. EB selectively inhibited CPY, not CPA and CPB, so that it in hibited urinary the CPY-like exopeptidase (Table 1) . EB did not inhibit kininases in plasma ( Table 2) . As EB did not inhibit rat urinary kallikrein (data not shown), which is also a serine esterase, the increased excretion of urinary kinin by EB was due to the kininase inhibition. The in creased excretion of urinary kinin by EB was accom panied with an increase in urine volume and urinary sodium levels, but not with urinary potassium levels, and these increases were completely suppressed by Hoel40. These results strongly suggest that urinary kinin induces diuresis and natriuresis and inhibition of degradation of BK by compounds such as EB may accelerate the excretion of urine volume and urinary sodium, since the BK receptor (B2) is present mainly on the collecting tubules (14) , which is different from the site of action of loop diuretics or thiazide derivatives. As we reported that the lack or reduced activity of urinary kallikrein-kinin system acceler ated the development of hypertension through reduced ex cretion of sodium and water in several models (8, 9, 15) , EB or other kininase inhibitor in the urine may be a candi date for a novel type of anti-hypertensive drug.
